Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine

Philipp Zimmer; Andreas Mierau; Wilhelm Bloch; Heiko K. Strüder; Thorben Hülsdünker; Alexander Schenk; Leonie Fiebig; Freek T. Baumann; Moritz Hahn; Nina Reinart; Michael Hallek; Thomas Elter

doi:10.3109/10428194.2014.915546

Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine

Leukemia & Lymphoma ◽

10.3109/10428194.2014.915546 ◽

2014 ◽

Vol 56 (2) ◽

pp. 347-352 ◽

Cited By ~ 32

Author(s):

Philipp Zimmer ◽

Andreas Mierau ◽

Wilhelm Bloch ◽

Heiko K. Strüder ◽

Thorben Hülsdünker ◽

...

Keyword(s):

Cognitive Impairment ◽

B Cell ◽

Hodgkin Lymphoma ◽

Cognitive Impairments ◽

Comprehensive Approach ◽

Non Hodgkin Lymphoma

Download Full-text

B-cell non-Hodgkin lymphoma (B-NHL) in patients with chronic hepatitis C. A report of 5 cases

Zeitschrift für Gastroenterologie ◽

10.1055/s-0033-1347495 ◽

2013 ◽

Vol 51 (05) ◽

Author(s):

I Nagy ◽

A Pálvölgyi ◽

S Modok ◽

T Wittmann

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

B Cell ◽

Hodgkin Lymphoma ◽

Chronic Hepatitis C ◽

Non Hodgkin Lymphoma

Download Full-text

B-Cell Non-Hodgkin Lymphoma

10.32388/91hm87 ◽

2020 ◽

Author(s):

Keyword(s):

B Cell ◽

Hodgkin Lymphoma ◽

Non Hodgkin Lymphoma

Download Full-text

Anti-Lipopolysaccharide Antibodies and Osmotic Resistance of Erythrocytes in Healthy Individuals and Patients with B-Cell Non-Hodgkin Lymphoma with Different Blood Groups

Mikrobiolohichnyi Zhurnal ◽

10.15407/microbiolj82.04.003 ◽

2020 ◽

Vol 82 (4) ◽

pp. 3-12

Author(s):

L.D. Varbanets ◽

◽

K.G. Garkava ◽

O.S. Brovarskaya ◽

T.V. Bulyhina ◽

...

Keyword(s):

B Cell ◽

Hodgkin Lymphoma ◽

Blood Groups ◽

Osmotic Resistance ◽

Healthy Individuals ◽

Non Hodgkin Lymphoma ◽

Osmotic Resistance Of Erythrocytes

Download Full-text

Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Case Medical Research ◽

10.31525/ct1-nct03886649 ◽

2019 ◽

Author(s):

Keyword(s):

B Cell ◽

Hodgkin Lymphoma ◽

Non Hodgkin Lymphoma

Download Full-text

Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Case Medical Research ◽

10.31525/ct1-nct04094142 ◽

2019 ◽

Author(s):

Keyword(s):

B Cell ◽

Hodgkin Lymphoma ◽

Non Hodgkin Lymphoma

Download Full-text

Phase II Trial of TisaGenlecleucel (Kymriah®) in Elderly Patients With First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma

Case Medical Research ◽

10.31525/ct1-nct04161118 ◽

2019 ◽

Author(s):

Keyword(s):

Elderly Patients ◽

B Cell ◽

Hodgkin Lymphoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Non Hodgkin Lymphoma

Download Full-text

Faculty Opinions recommendation of Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1072097.525084 ◽

2007 ◽

Author(s):

Emili Montserrat

Keyword(s):

Chronic Lymphocytic Leukemia ◽

B Cell ◽

Hodgkin Lymphoma ◽

Light Chain ◽

Free Light Chain ◽

Lymphocytic Leukemia ◽

Serum Free ◽

Serum Free Light Chain ◽

Non Hodgkin Lymphoma

Download Full-text

Faculty Opinions recommendation of IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.14265959.15778063 ◽

2012 ◽

Author(s):

Larry Kane ◽

Judong Lee

Keyword(s):

T Cell ◽

B Cell ◽

Hodgkin Lymphoma ◽

T Cell Exhaustion ◽

Cell Exhaustion ◽

Non Hodgkin Lymphoma

Download Full-text

Faculty Opinions recommendation of Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718499066.793521333 ◽

2016 ◽

Author(s):

Won Seog Kim

Keyword(s):

B Cell ◽

Hodgkin Lymphoma ◽

Non Hodgkin Lymphoma ◽

Treatment Naïve ◽

Phase 1B

Download Full-text

One Year of Maintenance Metronomic Cyclophosphamide, Methotreaxate & Celecoxib in High Risk Diffuse Large B Cell Non Hodgkin Lymphoma After Complete Response.

Research in Oncology ◽

10.21608/resoncol.2014.882 ◽

2014 ◽

Vol 10 (Issue 1-2) ◽

pp. 40-45

Author(s):

S. AlHassanin ◽

T. Hashem ◽

K. ElDin ◽

H. Kohail ◽

H. ElSheridy ◽

...

Keyword(s):

High Risk ◽

B Cell ◽

Hodgkin Lymphoma ◽

Complete Response ◽

Non Hodgkin Lymphoma ◽

One Year ◽

Metronomic Cyclophosphamide ◽

Large B Cell

Download Full-text